MOORE CLINICAL RESEARCH, INC.

George W Monlux Jr, MD
Clinical Investigator

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Research and Professional Experience:	
MOORE Clinical Research, Inc, Clinical Investigator	December 2018-Present
Clear Path Center, Staff Physician	January 2017-February 2017
Kenaday Medical, Medical Director	July 2015-January 2017
First Coast Pain Management, Medical Director	October 2014-May 2015
Affordable Healthcare, Medical Director	January 2014-October 2014
Kenaday Medical Clinic, Staff Physician	June 2013-December 2014
Samaritan Occupational Medicine Department, Chief Physician	January 2005-May 2013
Samaritan Urgent Care, Chief Physician	October 2002-January 2005
Veterans' Health Administration, Physician, PM&R Locums	September 2001-Nov. 2001
Private Practice, Concord, New Hampshire	September 1999-August 2001
Concord Orthopedics, Staff Physician	July 1996-August 1999
Dept of Physical Medicine & Rehabilitation Tufts, Resident	July 1993-June 1996
Back Clinic Tufts Dept. of PM&R, Physician, Locums	March 1993-June 1993
Virginia Mason Clinic, Occupational Medicine Physician	August 1992-January 1993
Providence Hospital Occupational Medicine Clinic, Staff Physician	July 1991-December 1993
Back in Action Clinic, Medical Director	July 1991-August 1992
Evergreen Surgery Center, Orthopedic Surgery Assistant	December 1990-August 1991
Med Idea Inc., CEO, Medical Director	August 1987-June 1991
MedAlaska Inc, CEO, Physician	February 1981-August 1987
Solo Family Practice, Assisting Surgeon	Dec. 1978-Dec. 1981
Kaiser Medical Center, Emergency Medicine, Chief Surgeon	July 1975-December 1978
Madigan Medical Center, Emergency Physician	July 1974-June 1975
United States Army, 25th Infantry, General Medical Officer, First Brigade Surgeon	July 1972-June 1974

Education and Postdoctoral Training:	
Residency, Physical Medicine and Rehabilitation, Tufts School of Medicine, Boston MA	June 1996
Rotating Internship, Tripler Medical Center, Honolulu, HI	July 1971
Doctor of Medicine, University of Washington School of Medicine, Seattle, WA	June 1971
Experimental Pathology, University of Washington School of Medicine, Seattle, WA	June 1967
Bachelors in Zoology, University of Washington School of Medicine, Seattle, WA	June 1965
Associates Degree in Art, Everett Community College, Everett, WA	June 1963

Publications:
Monlux G., Smuckler E. *An autoradiographic study of protein synthesis in mouse liver parenchymal cells during CCl_4 intoxication.* Journal of Pathology 1969; Vol 54 No. 1: 73-82.
Rainville J., Monlux G., et al. *Decreasing disability in chronic back pain through aggressive spine rehabilitation.* Journal of Rehabilitation Research and Development 1997; Vol 34, No. 4: 383-393

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

MOORE CLINICAL RESEARCH, INC.

George W Monlux Jr, MD
Clinical Investigator

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Licenses/Certifications/Memberships:	
State of Florida Medical License ME 116322, DEA FM7947596	January 2021
Board Certified, American Board of Family Medicine	April 2017
Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations	December 2018
BLS for Healthcare Providers, American Heart Association	May 2021
ACLS for Healthcare Providers, American Heart Association	June 2021

Training:	
Comprehensive SOP Review	January 2020
Adverse Event Collection and Reporting in Clinical Research	January 2019
Bloodborne Pathogens & Biomedical Waste Management	January 2019
Comprehensive SOP Review	January 2019
Responsible Conduct of Research, CITI Program	January 2019
Good Clinical Practice, NIH Training	January 2019
Human Subject Assurance Training	January 2019

Clinical Trial Experience:

ACNE VULGARIS (Validated Acne Rater)

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.1% (XXXX) to Differin Gel (Adapalene 0.1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2020, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% (XXXX) to Retin-A® (Tretinoin) Cream 0.025% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle Controlled Study of XXXX in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1%, XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Phase 2, Randomized, Multicenter, Double-Blind, Vehicle Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Daily for 12 Weeks in Subjects with Facial Acne Vulgaris for Treatment of Moderate to Severe Inflammatory Acne Vulgaris" 2019, Sub-Investigator

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

ACTINIC KERATOSIS

"A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-center, Therapeutic Equivalence Study of Two Fluorouracil 5% Topical Cream Formulations in Adult Subjects with Multiple Actinic Lesions." 2019, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Bioequivalence Study to Compare XXXX 5-FU Cream 5%, with Efudex (5-FU) Cream 5%, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis." 2019, Sub-Investigator

ATOPIC DERMATITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019 Sub-Investigator

INFLUENZA

"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza." 2018, Sub-Investigator

PSORIASIS

"A Double-Blind, Randomized, Multicenter, Vehicle Controlled, Parallel Group Comparison Study to Determine the Efficacy and Safety of Halobestasol Propionate Spray, 0.05% Versus Vehicle Spray in Subjects with Plaque Psoriasis Receiving Up to Four Weeks of Twice Daily Treatment." 2018, Principal Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calciotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris." 2019 Sub-Investigator

"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of XXXXX in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018, Sub-Investigator

"A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-Severe Plaque Psoriasis.: 2018, Sub-Investigator

ROSACEA

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2019, Sub-Investigator

"A Multi-Center, Open-Label, Long-Term Safety Study of XXXX to Evaluate the Safety of XXXX in Papulopustular Rosacea Patients." 2018, Principal Investigator

SCALP PSORIASIS

Note: Electronic signature for this document is a Part 11 compliant signature produced via RealTime CTMS eDOCS

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis." 2018, Sub-Investigator

TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019, Principal Investigator